237 related articles for article (PubMed ID: 28501938)
1. Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2
Fowler DW; Copier J; Dalgleish AG; Bodman-Smith MD
Cancer Immunol Immunother; 2017 Sep; 66(9):1205-1215. PubMed ID: 28501938
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid enhances Vδ2 T-lymphocyte antitumor response to human glioma cell lines.
Cimini E; Piacentini P; Sacchi A; Gioia C; Leone S; Lauro GM; Martini F; Agrati C
Int J Immunopathol Pharmacol; 2011; 24(1):139-48. PubMed ID: 21496396
[TBL] [Abstract][Full Text] [Related]
3. The effect of zoledronic acid on type and volume of Modic changes among patients with low back pain.
Koivisto K; Järvinen J; Karppinen J; Haapea M; Paananen M; Kyllönen E; Tervonen O; Niinimäki J
BMC Musculoskelet Disord; 2017 Jun; 18(1):274. PubMed ID: 28645291
[TBL] [Abstract][Full Text] [Related]
4. Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vγ9Vδ2 T cells, αβ CD8+ T cells, regulatory T cells, and dendritic cells.
Castella B; Riganti C; Fiore F; Pantaleoni F; Canepari ME; Peola S; Foglietta M; Palumbo A; Bosia A; Coscia M; Boccadoro M; Massaia M
J Immunol; 2011 Aug; 187(4):1578-90. PubMed ID: 21753152
[TBL] [Abstract][Full Text] [Related]
5. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.
Poonia B; Pauza CD
Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activity of human Vδ2 T-cells against WNV includes both cytolytic and non-cytolytic mechanisms.
Agrati C; Castilletti C; Cimini E; Romanelli A; Lapa D; Quartu S; Martini F; Capobianchi MR
New Microbiol; 2016 Apr; 39(2):139-42. PubMed ID: 27196553
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid prevents the tumor-promoting effects of mesenchymal stem cells via MCP-1 dependent recruitment of macrophages.
Jia XH; Du Y; Mao D; Wang ZL; He ZQ; Qiu JD; Ma XB; Shang WT; Ding D; Tian J
Oncotarget; 2015 Sep; 6(28):26018-28. PubMed ID: 26305552
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid causes γδ T cells to target monocytes and down-modulate inflammatory homing.
Fowler DW; Copier J; Dalgleish AG; Bodman-Smith MD
Immunology; 2014 Dec; 143(4):539-49. PubMed ID: 24912747
[TBL] [Abstract][Full Text] [Related]
9. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.
Lang JM; Kaikobad MR; Wallace M; Staab MJ; Horvath DL; Wilding G; Liu G; Eickhoff JC; McNeel DG; Malkovsky M
Cancer Immunol Immunother; 2011 Oct; 60(10):1447-60. PubMed ID: 21647691
[TBL] [Abstract][Full Text] [Related]
10. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
Qiao H; Wang TY; Yan W; Qin A; Fan QM; Han XG; Wang YG; Tang TT
Acta Pharmacol Sin; 2015 Sep; 36(9):1085-98. PubMed ID: 26235741
[TBL] [Abstract][Full Text] [Related]
11. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients.
Santini D; Martini F; Fratto ME; Galluzzo S; Vincenzi B; Agrati C; Turchi F; Piacentini P; Rocci L; Manavalan JS; Tonini G; Poccia F
Cancer Immunol Immunother; 2009 Jan; 58(1):31-8. PubMed ID: 18458903
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid inhibits the function of Toll-like receptor 4 ligand activated monocyte-derived dendritic cells.
Bringmann A; Schmidt SM; Weck MM; Brauer KM; von Schwarzenberg K; Werth D; Grünebach F; Brossart P
Leukemia; 2007 Apr; 21(4):732-8. PubMed ID: 17301819
[TBL] [Abstract][Full Text] [Related]
13. Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN-γ.
Sarhan D; D'Arcy P; Wennerberg E; Lidén M; Hu J; Winqvist O; Rolny C; Lundqvist A
Eur J Immunol; 2013 Jan; 43(1):249-57. PubMed ID: 22996291
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid.
Inoue Y; Oda A; Maeda Y; Sumitani R; Oura M; Sogabe K; Maruhashi T; Takahashi M; Fujii S; Nakamura S; Miki H; Hiasa M; Teramachi J; Harada T; Abe M
Int J Hematol; 2024 Jun; 119(6):626-630. PubMed ID: 38581458
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
16. Bacillus Calmette-Guerin (BCG) induces superior anti-tumour responses by Vδ2+ T cells compared with the aminobisphosphonate drug zoledronic acid.
Fenn J; Ridgley LA; White A; Sarfas C; Dennis M; Dalgleish A; Reljic R; Sharpe S; Bodman-Smith M
Clin Exp Immunol; 2022 Jun; 208(3):301-315. PubMed ID: 35404420
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells.
Märten A; Lilienfeld-Toal Mv; Büchler MW; Schmidt J
J Immunother; 2007; 30(4):370-7. PubMed ID: 17457212
[TBL] [Abstract][Full Text] [Related]
18. Markers of inflammation after zoledronic acid redosing.
Sykiotis A; Papaioannou G; Mavropoulos J; Triantaphyllopoulou M; Papandroulaki F; Ktena V; Thanou S; Pardalakis A; Kaltsa A; Karga H
J Bone Miner Metab; 2014 Jan; 32(1):72-7. PubMed ID: 23690161
[TBL] [Abstract][Full Text] [Related]
19. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.
Mariani S; Muraro M; Pantaleoni F; Fiore F; Nuschak B; Peola S; Foglietta M; Palumbo A; Coscia M; Castella B; Bruno B; Bertieri R; Boano L; Boccadoro M; Massaia M
Leukemia; 2005 Apr; 19(4):664-70. PubMed ID: 15744346
[TBL] [Abstract][Full Text] [Related]
20. Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis.
Verdrengh M; Carlsten H; Ohlsson C; Tarkowski A
J Orthop Res; 2007 Mar; 25(3):304-10. PubMed ID: 17089391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
